scispace - formally typeset
X

Xiaoju Max Ma

Researcher at Harvard University

Publications -  8
Citations -  3408

Xiaoju Max Ma is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 3 publications receiving 3103 citations. Previous affiliations of Xiaoju Max Ma include Genentech.

Papers
More filters
Journal ArticleDOI

Molecular mechanisms of mTOR-mediated translational control

TL;DR: Recent findings on the regulators and effectors of mTOR are highlighted and specific cases that serve as paradigms for the different modes of m TOR regulation and its control of translation are discussed.
Journal ArticleDOI

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

TL;DR: A search for substrates of a growth-promoting kinase revealed a regulatory feedback loop involved in tumor suppression, and large-scale quantitative phosphoproteomics experiments were used to define the signaling networks downstream of mTORC1 and m TORC2.
Journal ArticleDOI

SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs.

TL;DR: SKAR-mediated recruitment of activated S6K1 to newly processed mRNPs serves as a conduit between mTOR checkpoint signaling and the pioneer round of translation when cells exist in conditions supportive of protein synthesis.
Journal ArticleDOI

Assessment of health risk and dose-effect of DNA oxidative damage for the thirty chemicals mixture of parabens, triclosan, benzophenones, and phthalate esters.

TL;DR: The relationship between 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels and chemical exposure was estimated by Bayesian kernel machine regression (BKMR) models as discussed by the authors .
Journal ArticleDOI

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

TL;DR: It is demonstrated that using liquid biopsies to measure early changes in ctDNA levels in response to chemotherapy may help identify non-responders before standard-of-care imaging in advanced NSCLC and monitor treatment efficacy earlier and accurately can enable more personalized regimens to improve patient outcomes.